Seattle Genetics, Astellas get FDA breakthrough therapy designation for enfortumab vedotin locally advanced or metastatic urothelial cancer

This article was originally published here

Seattle Genetics, and Astellas Pharma have secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for enfortumab vedotin, an antibody-drug conjugate (ADC), to treat patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply